Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose first-in-human safety study of PB006 infusion in healthy volunteers
NL-OMON48246Completed
- Sponsor
- Bioeq AG
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of PB006 in multiple sclerosis (MS), sponsored by Bioeq AG. Primary endpoints: Safety and Tolerability. Started Mar 2019; status: completed.
02
Drugs
PB006
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON48246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48246.